UNSPSC 51292007: Melitracen

This classification denotes an anthracene and tricyclic antidepressive agent with the molecular formula C21H25N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q7T0Y1109Z, chemically known as 3-(10,10-dimethyl-9(10h)-anthracenylidene)-n,n-dimethyl-1-propanamine but generally known as melitracen, which bears US NIH Compound Identifier 25382. European Medicines Agency schedules Melitracen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08725MIG.

UNSPSC 51292007 Melitracen is a Commodity code that in recent state and local procurement captures a broader range of pharmaceutical products and drug-related supplies than the code name alone suggests. State and local governments soliciting under this code are actually procuring naloxone and drug deactivation systems, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription fulfillment programs — reflecting community health, emergency response, and pharmacy benefit management across a mix of county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. Issuing bodies include county-level health agencies (Seminole County, Florida), state health departments (Texas HHS Commission), and state procurement offices administering cooperative purchasing agreements (Minnesota Department of Administration through MMCAP, which includes participating jurisdictions across multiple states). The code shows activity driven by health benefit modernization, controlled-substance access programs, and pharmaceutical supply chain optimization rather than a single product category.

Geographic activity centers on Florida and Texas with multistate reach through cooperative purchasing agreements. Seminole County, Florida issued an IFB (IFB60459723LAS, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, using a two-year contract term with optional one-year renewal and E-Verify compliance and workers' compensation insurance requirements. The Texas Health and Human Services Commission issued an RFI (HHS0017013, posted April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription program vendors, requesting information on direct contracting capacity, negotiated net pricing models, and outcomes-based agreement capability without specifying award values or formal evaluation timelines. The Minnesota Department of Administration issued a multistate RFP through MMCAP (S1070000015802, due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products with distribution across Minnesota and Oregon, requiring NDC codes, cGMP certification, DSCSA compliance, and pricing submission through authorized wholesalers with a July 1, 2026 effective date for awarded contracts.